As the Democratic Republic of the Congo and surrounding regions confront the fastest-growing Ebola outbreak on record, GeoVax Labs, Inc. (Nasdaq: GOVX) has underscored the potential relevance of its MVA-based vaccine platform and hemorrhagic fever vaccine candidates to the global response. The outbreak, caused by the Bundibugyo virus (BDBV), has already resulted in more than 4,300 cases and 2,000 deaths, according to the World Health Organization (WHO), and is on a trajectory that could surpass the death toll of the 2014-2016 West Africa epidemic. Currently, no approved vaccine exists specifically for Bundibugyo virus.
GeoVax, a biotechnology company developing vaccines and immunotherapies for infectious diseases and cancers, has extensive preclinical experience with vaccines against high-consequence hemorrhagic fever viruses, including Zaire ebolavirus, Sudan ebolavirus, and Marburg virus. These candidates have demonstrated protective efficacy in non-human primate lethal-challenge studies. The company's MVA platform, which forms the basis of its lead infectious disease program GEO-MVA for mpox and smallpox, offers a versatile foundation for addressing emerging viral threats.
David Dodd, Chairman and CEO of GeoVax, emphasized the importance of preparedness: "The rapidly escalating Ebola Bundibugyo outbreak underscores the importance of having vaccine technologies and capabilities available before a crisis occurs. We are prepared to engage with WHO, Africa CDC, national public health authorities, and other appropriate organizations to determine whether our vaccine candidates, technology, or scientific expertise could contribute to the response." The company is also open to making relevant vaccine materials available for evaluation against Bundibugyo virus.
GeoVax's existing relationships in Africa, developed primarily to advance GEO-MVA's pivotal clinical program, provide a natural avenue for collaboration. Portions of the planned immunobridging study for GEO-MVA are expected to be conducted in African regions facing significant infectious disease challenges, including areas affected by the current Ebola outbreak. These connections could facilitate a coordinated public health response, as many organizations engaged for GEO-MVA are simultaneously dealing with Ebola.
Beyond GEO-MVA, GeoVax retains a portfolio of MVA-based hemorrhagic fever vaccine candidates that have shown promise in animal models. These programs represent strategic optionality, and the company is open to collaborations, licensing arrangements, or public-private partnerships that could further evaluate and develop these assets without diverting resources from GEO-MVA. The company believes its combination of MVA platform expertise, vaccine candidates, and scalable manufacturing capabilities provides a foundation for meaningful contributions to outbreak responses.
The significance of this announcement lies in the urgent global need for vaccines against emerging pathogens. With the Congo outbreak expanding and no approved Bundibugyo vaccine, GeoVax's willingness to share its expertise and candidates could accelerate the development of a protective measure. Moreover, the company's strategic focus on expanding MVA vaccine supply through GEO-MVA, including innovations in continuous cell-line manufacturing and single-dose regimens, positions it to address both current and future infectious disease threats.
For more information about GeoVax and its programs, visit GeoVax's website.
